Real-World Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-Balloon for Detection of Barrett’s Esophagus (BE)
<i>Background:</i> Barrett’s Esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EAC). Patients with multiple risk factors for BE/EAC are recommended for screening; however, few eligible patients undergo evaluation by endoscopy. EsoGuard<sup>®</sup> (EG)...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/60/12/2052 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850086926875361280 |
|---|---|
| author | Dan Lister Andy Fine Shail Maheshwari Paul S. Bradley Kimberly Lister Victoria T. Lee Brian J. deGuzman Suman Verma Lishan Aklog |
| author_facet | Dan Lister Andy Fine Shail Maheshwari Paul S. Bradley Kimberly Lister Victoria T. Lee Brian J. deGuzman Suman Verma Lishan Aklog |
| author_sort | Dan Lister |
| collection | DOAJ |
| description | <i>Background:</i> Barrett’s Esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EAC). Patients with multiple risk factors for BE/EAC are recommended for screening; however, few eligible patients undergo evaluation by endoscopy. EsoGuard<sup>®</sup> (EG) is a commercially available biomarker assay used to analyze esophageal cells collected non-endoscopically with EsoCheck<sup>®</sup> (EC) for the qualitative detection of BE/EAC. This study evaluates the real-world clinical utility of EG on cells collected with EC in patients defined by U.S. gastroenterology societies to be at-risk for BE and EAC. <i>Methods:</i> This multi-center, observational <b>CL</b>inical <b>U</b>tility of <b>E</b>soGuard (CLUE) study enrolled screening-eligible patients as defined by the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA). Clinical utility was evaluated by the provider decision impact of EG and additionally by assessing patient compliance outcomes with recommended follow-up testing. <i>Results:</i> There were 551 patients enrolled, with a mean age of 62.0 ± 12.4 years and 56.1% (309/551) meeting ACG guideline criteria for BE screening. EC cell collection was successful in 97.1% (535/551), among which the EG positivity rate was 27.3% (<i>n</i> = 146). The provider decision impact was high, with 100% of EG-positive patients being referred for esophagogastroduodenoscopy (EGD), while 98% of EG negative patients were not referred. Among the EG-positive patients, the overall compliance with follow-up EGD was 85.4%. <i>Conclusions:</i> Combining EC non-endoscopic esophageal cell collection with the EG biomarker assay is effective in guiding provider decision-making for the detection of BE and EAC. Patients with positive EG results demonstrate high compliance with recommended follow-up EGD. |
| format | Article |
| id | doaj-art-a684effd97ba4466ae0292f1f5fc77be |
| institution | DOAJ |
| issn | 1010-660X 1648-9144 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj-art-a684effd97ba4466ae0292f1f5fc77be2025-08-20T02:43:20ZengMDPI AGMedicina1010-660X1648-91442024-12-016012205210.3390/medicina60122052Real-World Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-Balloon for Detection of Barrett’s Esophagus (BE)Dan Lister0Andy Fine1Shail Maheshwari2Paul S. Bradley3Kimberly Lister4Victoria T. Lee5Brian J. deGuzman6Suman Verma7Lishan Aklog8Arkansas Heartburn Treatment Center, Heber Springs, AR 72543, USAColorado Primary Health Care, Littleton, CO 80120, USACenter for Digestive Disease, Shenandoah, TX 77384, USASavii Health, Savannah, GA 31406, USAArkansas Heartburn Treatment Center, Heber Springs, AR 72543, USALucid Diagnostics Inc., New York, NY 10017, USALucid Diagnostics Inc., New York, NY 10017, USALucid Diagnostics Inc., New York, NY 10017, USALucid Diagnostics Inc., New York, NY 10017, USA<i>Background:</i> Barrett’s Esophagus (BE) is the only known precursor for esophageal adenocarcinoma (EAC). Patients with multiple risk factors for BE/EAC are recommended for screening; however, few eligible patients undergo evaluation by endoscopy. EsoGuard<sup>®</sup> (EG) is a commercially available biomarker assay used to analyze esophageal cells collected non-endoscopically with EsoCheck<sup>®</sup> (EC) for the qualitative detection of BE/EAC. This study evaluates the real-world clinical utility of EG on cells collected with EC in patients defined by U.S. gastroenterology societies to be at-risk for BE and EAC. <i>Methods:</i> This multi-center, observational <b>CL</b>inical <b>U</b>tility of <b>E</b>soGuard (CLUE) study enrolled screening-eligible patients as defined by the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA). Clinical utility was evaluated by the provider decision impact of EG and additionally by assessing patient compliance outcomes with recommended follow-up testing. <i>Results:</i> There were 551 patients enrolled, with a mean age of 62.0 ± 12.4 years and 56.1% (309/551) meeting ACG guideline criteria for BE screening. EC cell collection was successful in 97.1% (535/551), among which the EG positivity rate was 27.3% (<i>n</i> = 146). The provider decision impact was high, with 100% of EG-positive patients being referred for esophagogastroduodenoscopy (EGD), while 98% of EG negative patients were not referred. Among the EG-positive patients, the overall compliance with follow-up EGD was 85.4%. <i>Conclusions:</i> Combining EC non-endoscopic esophageal cell collection with the EG biomarker assay is effective in guiding provider decision-making for the detection of BE and EAC. Patients with positive EG results demonstrate high compliance with recommended follow-up EGD.https://www.mdpi.com/1648-9144/60/12/2052Barrett’s esophagusesophageal adenocarcinomaEsoGuardEsoCheckclinical utilityscreening |
| spellingShingle | Dan Lister Andy Fine Shail Maheshwari Paul S. Bradley Kimberly Lister Victoria T. Lee Brian J. deGuzman Suman Verma Lishan Aklog Real-World Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-Balloon for Detection of Barrett’s Esophagus (BE) Medicina Barrett’s esophagus esophageal adenocarcinoma EsoGuard EsoCheck clinical utility screening |
| title | Real-World Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-Balloon for Detection of Barrett’s Esophagus (BE) |
| title_full | Real-World Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-Balloon for Detection of Barrett’s Esophagus (BE) |
| title_fullStr | Real-World Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-Balloon for Detection of Barrett’s Esophagus (BE) |
| title_full_unstemmed | Real-World Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-Balloon for Detection of Barrett’s Esophagus (BE) |
| title_short | Real-World Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-Balloon for Detection of Barrett’s Esophagus (BE) |
| title_sort | real world clinical utility of a methylated dna biomarker assay on samples collected with a swallowable capsule balloon for detection of barrett s esophagus be |
| topic | Barrett’s esophagus esophageal adenocarcinoma EsoGuard EsoCheck clinical utility screening |
| url | https://www.mdpi.com/1648-9144/60/12/2052 |
| work_keys_str_mv | AT danlister realworldclinicalutilityofamethylateddnabiomarkerassayonsamplescollectedwithaswallowablecapsuleballoonfordetectionofbarrettsesophagusbe AT andyfine realworldclinicalutilityofamethylateddnabiomarkerassayonsamplescollectedwithaswallowablecapsuleballoonfordetectionofbarrettsesophagusbe AT shailmaheshwari realworldclinicalutilityofamethylateddnabiomarkerassayonsamplescollectedwithaswallowablecapsuleballoonfordetectionofbarrettsesophagusbe AT paulsbradley realworldclinicalutilityofamethylateddnabiomarkerassayonsamplescollectedwithaswallowablecapsuleballoonfordetectionofbarrettsesophagusbe AT kimberlylister realworldclinicalutilityofamethylateddnabiomarkerassayonsamplescollectedwithaswallowablecapsuleballoonfordetectionofbarrettsesophagusbe AT victoriatlee realworldclinicalutilityofamethylateddnabiomarkerassayonsamplescollectedwithaswallowablecapsuleballoonfordetectionofbarrettsesophagusbe AT brianjdeguzman realworldclinicalutilityofamethylateddnabiomarkerassayonsamplescollectedwithaswallowablecapsuleballoonfordetectionofbarrettsesophagusbe AT sumanverma realworldclinicalutilityofamethylateddnabiomarkerassayonsamplescollectedwithaswallowablecapsuleballoonfordetectionofbarrettsesophagusbe AT lishanaklog realworldclinicalutilityofamethylateddnabiomarkerassayonsamplescollectedwithaswallowablecapsuleballoonfordetectionofbarrettsesophagusbe |